AzTrials
AzTrials

CannabidiolPhase 1NCT06192589

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

A Phase 1 study testing Cannabidiol, Citalopram and Morphine in people with Cannabidiol and Drug Induced Liver Injury, run by Food and Drug Administration (FDA) at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
What is being tested?
Cannabidiol, Citalopram and Morphine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
241 participants
Where
1 siteUnited States
Study dates
8 Feb 2024to 6 Sep 2024
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Subject signs an institutional review board (IRB) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization) before any study related procedures are performed.
  • Subject is a healthy, non-smoking man or woman, 18 to 55 years of age, inclusive, who weighs at least 50 kg (110 lbs) and has a body mass index of 18.5 to 33.0 kg/m2, inclusive, at Screening and check-in (Day -1).
  • Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
  • Subject must have a negative test result for alcohol and illicit drugs at screening and check-in (Day -1).
  • Participants must agree to refrain from using any of the following for the duration of the study: alcohol, nicotine containing products, marijuana or marijuana-derived products, hemp or hemp-derived products, including CBD (except for provided study drug), and illicit drugs of any kind.
  • Subject must test negative for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) by a rapid antigen test at check-in for all study periods. If a subject's test comes back as invalid, the test can be repeated.
Show all 9Show fewer
  • Female subjects must be of non-childbearing potential (non-childbearing potential includes post-menopausal females defined as spontaneous amenorrhea for at least 12 months with FSH in the post-menopausal range and females who have undergone a hysterectomy) or, if they are of childbearing potential, they must: 1) have negative serum HCG at screening and check-in 2) have been strictly abstinent for 1 month before check-in (Day -1) and agree to remain strictly abstinent for the duration of the study and for at least 1 month after the last application of study drug; OR 3) be practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until at least 1 month after the end of the study.
  • Male subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee) beginning at check-in (Day -1) until at least 3 months after the last dose of study drug. Male subjects may not donate sperm for 90 days after the end of the study.
  • Subject agrees to and is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.

Who cannot join

  • Abnormal liver labs at screening on check-in (Day -1), defined as any of the following (tests may be repeated once for confirmation at screening and check-in):
  • Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 × ULN. (The ULN for ALT will be 33 U/L for males and 25 U/L for females.)
  • Total bilirubin (TBL) > ULN.
  • International normalized ratio (INR) > 1.3
  • Use or intend to use any medications/products in the 14 days prior to check-in (Day -1), unless deemed acceptable by the investigator
  • Subject is currently participating in another clinical study of an investigational drug or has been treated with any investigational drug within 30 days or 5 half-lives (whichever is longer) of dosing for this study.
Show all 27Show fewer
  • Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, electronic cigarettes) within 6 weeks of Screening. Subjects must refrain from using these throughout the study.
  • Subject has consumed alcohol, xanthine-containing products (e.g., tea, coffee, chocolate, cola), caffeine, kava melatonin, St Johns Wart, grapefruit, or grapefruit juice within 24 hours of check-in. Subjects must refrain from ingesting these throughout the study.
  • Subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points (e.g., before and during CBD dosing).
  • Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months before Screening, has a history of alcoholism or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor)
  • Subject has a positive test result for alcohol or drugs of misuse (amphetamines, barbiturates, benzodiazepines, cocaine, alcohol, opiates, phencyclidine, propoxyphene, and methadone) at Screening or Check-in (Day -1 [both Parts]; Day 10 [Part 2, morphine DDI]; Day 12 [Part 2, citalopram DDI]).
  • Subject has a positive test result for cannabinoids (THC) at screening or Day -1.
  • Subject has a history of opioid or narcotic misuse.
  • Subject has a history of suicidal ideation or previous suicide attempts
  • Subject has a history or evidence of a clinically significant disorder, condition, or disease (e.g., cancer, human immunodeficiency virus [HIV], hepatic or renal impairment) that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Subject has any signs or symptoms that are consistent with Coronavirus Disease 2019 (COVID-19) per Center for Disease Control (CDC) recommendations at screening or check-in (Day -1). These include subjects with fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea may have COVID-19. In addition, the subject has any other findings suggestive of COVID-19 risk in the opinion of the investigator.
  • Subject has known or suspected allergies or sensitivities to the study drug or placebo components (e.g., sucralose, sesame).
  • Subjects with a documented hypersensitivity reaction to cannabidiol
  • Subjects with a documented medical history of clinical disorders related to mood, anxiety or panic, including diagnosed depression, generalized anxiety disorder or panic attacks.
  • Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome). Uncomplicated cholecystectomies and appendectomies may be included at the investigator's discretion.
  • Subject has clinical laboratory test results (hematology, serum chemistry and urinalysis) at Screening or Check-In that are outside the reference ranges provided by the clinical laboratory and considered clinically significant by the investigator. Tests may be repeated once for confirmation at both Screening and Check-In.
  • Subject has a positive test result at Screening for HIV 1 or 2 antibody, hepatitis C virus antibodies, or hepatitis B surface antigen.
  • Subject has a mean systolic blood pressure <85 or >145 mmHg or a mean diastolic blood pressure <45 or >95 mmHg at either Screening or Check-in. Blood pressure will be measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.
  • Subject is unable or unwilling to undergo multiple venipunctures for blood sample collection because of poor tolerability or is unlikely to complete the study due to poor venous access.
  • Female subject is currently pregnant or lactating or was within 3 months of the study.
  • Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before Check-in.
  • Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Spaulding Clinical Research

    West Bend, Wisconsin, 53095

Other trials in United States

About this study

Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with lower CBD doses with unapproved consumer products highlights a need for further research. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.

The objective of this study is to characterize the effects of daily CBD use at a dose within the range of what consumers are taking as unapproved CBD products on liver enzyme elevations, drug interactions, and endocrine measures.

Read the detailed description

The cannabis plant contains bioactive compounds known as cannabinoids; delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent cannabinoids in most varieties of cannabis. The Agricultural Improvement Act (Farm Bill) of 2018 removed hemp, defined as cannabis and derivatives of cannabis with extremely low concentrations of THC, from the definition of marijuana in the Controlled Substances Act. Following this, many CBD products have been made available to consumers. However, hemp products remain subject to regulation under the Federal Food Drug \& Cosmetic Act, when applicable (e.g., as drugs, foods, dietary supplements, cosmetics, veterinary products) and the growing CBD products market raises various safety concerns, especially with long-term use.

CBD is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with CBD doses in unapproved consumer products highlights a need for further research to quantify risks at these doses. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.

This study will be divided into two parts.

In Part 1, 200 healthy subjects will be randomized to 5 mg/kg/day of CBD (150 subjects) or placebo (50 subjects) for 4 weeks with weekly laboratory assessments to characterize the percentage of participants with liver enzyme elevation (primary endpoint) or meeting withdrawal criteria for potential drug-induced liver injury (secondary endpoint). Additional secondary endpoints include the change from baseline after 4 weeks of daily CBD dosing for male reproductive (testosterone and inhibin B) and thyroid hormones (thyroid stimulating hormone [TSH], triiodothyronine [T3] and thyroxine [T4]) as secondary endpoints. Exploratory endpoints include additional characterization of liver findings and other blood biomarkers.

In Part 2, 40 healthy subjects will receive either oral citalopram (20 subjects) or morphine (20 subjects) at baseline and then again after receiving CBD 5 mg/kg/day to characterize the effect of daily cannabidiol use on the plasma concentration of citalopram and morphine. Citalopram was selected because it is a common prescription medication for depression and anxiety that is metabolized by CYP2C19 and CYP3A4, which CBD inhibits. Morphine was selected because it is a common opioid analgesic that is metabolized by UGT2B7, which CBD inhibits.

Being tested
Cannabidiol, Placebo, Citalopram, Morphine
Keywords
Cannabidiol, CBD, Liver enzyme elevation, Drug interactions
Medical subject headings
Chemical and Drug Induced Liver Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CannabidiolDrug

    Also called Epidiolex

    Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.

  • PlaceboDrug

    Placebo will be administered orally twice daily for 28 days in Part 1

  • CitalopramDrug

    Also called Celexa

    Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.

  • MorphineDrug

    Morphine will be administered once at 15 mg on days 1, 4, and 11.

Study groups in NCT06192589
Study groupRoleWhat they receive
Cannabidiol (Part 1)Active comparatorSubjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days.
Receives: Drug: Cannabidiol
Placebo (Part 1)Placebo comparatorSubjects in this arm will receive oral solution placebo twice a day for 28 days.
Receives: Drug: Placebo
Cannabidiol and Citalopram Drug Interaction (Part 2)Active comparatorSubjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17).
Receives: Drug: Cannabidiol; Drug: Citalopram
Cannabidiol and Morphine Drug Interaction (Part 2)Active comparatorSubjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12).
Receives: Drug: Cannabidiol; Drug: Morphine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN).

    The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females.

    Measured: Days 1 through 35

  2. Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.

    Measured: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)

  3. Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.

    Measured: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)

  4. Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.

    Measured: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  5. Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.

    Measured: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

Secondary outcomes (10)

  1. Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI).

    Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria.

    • ALT or AST > 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%) OR
    • ALT elevation ≥ 5 × ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) OR
    • Alkaline phosphatase (ALP) elevation ≥ 2 × ULN (with accompanying elevations of gamma-glutamyl transpeptidase (GGT) in the absence of known bone pathology driving the rise in ALP level) OR
    • ALT elevation ≥ 3 × ULN and bilirubin concentration > 2 × ULN

    Measured: Days 1 through 35

  2. Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Measured: Days 1 and 29

  3. Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Measured: Days 1 and 29

  4. Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Measured: Days 1 and 29

  5. Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Measured: Days 1 and 29

  6. Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Measured: Days 1 and 29

  7. Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.

    Measured: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  8. Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.

    Measured: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  9. Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.

    Measured: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  10. Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.

    Measured: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2024
  2. Study start8 Feb 2024
  3. Primary completion6 Sep 2024
  4. Study completion6 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a two-part study. Part 1 is a randomized, double-blind, placebo-controlled, parallel study in 200 subjects (150 subjects receiving cannabidiol and 50 subjects receiving placebo). Part 2 is an open-label, sequential study in 40 subjects (two separate cohorts of 20 subjects).
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
241 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06192589
Sponsor's protocol ID
SCR-016
Status last verified
Jul 2025
First submitted
18 Dec 2023
Last updated
31 Jul 2025
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Plan is to make data from the study publicly available as part of a manuscript publication. In addition, the protocol and statistical analysis plan will be made available online at this site as well as with any eventual publications.

Publications

  • 1. U.S. Food and Drug Administration (FDA) Science Board. (2022, June 3). Background materials for the June 14, 2022 meeting of the Science Board to the FDA. Retrieved from https://www.fda.gov/advisory-committees/advisory-committee-roster/science-board-fda/2022-meetings#event-materials.

  • 2. Cannabidiol (Epidiolex ®) oral solution label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf

  • Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023 Jun;293(6):724-752. doi: 10.1111/joim.13627. Epub 2023 Mar 13.

    PubMed 36912195

  • Crippa JAS, Zuardi AW, Guimaraes FS, Campos AC, de Lima Osorio F, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Pereira-Lima K, Sen S, Andraus MH, Hallak JEC; Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. doi: 10.1001/jamanetworkopen.2021.20603.

    PubMed 34387679

  • 5. U.S. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf

  • 6. EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck, D, Bohn, T, Castenmiller, J, De Henauw, S, Hirsch-Ernst, KI, Maciuk, A, Mangelsdorf, I, McArdle, HJ, Naska, A, Pelaez, C, Pentieva, K, Siani, A, Thies, F, Tsabouri, S, Vinceti, M, Cubadda, F, Frenzel, T, Heinonen, M, Marchelli, R, Neuhäuser-Berthold, M, Poulsen, M, Prieto Maradona, M, Schlatter, JR, Trezza, V, van Loveren, H, Albert, O, Dumas, C, Germini, A, Gelbmann, W, Kass, G, Kouloura, E, Noriega Fernandez, E, Rossi, A and Knutsen, HK, 2022. Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA Journal 2022; 20(6):7322, 25 pp. https://doi.org/10.2903/j.efsa.2022.7322

  • Carvalho RK, Andersen ML, Mazaro-Costa R. The effects of cannabidiol on male reproductive system: A literature review. J Appl Toxicol. 2020 Jan;40(1):132-150. doi: 10.1002/jat.3831. Epub 2019 Jul 17.

    PubMed 31313338

  • Tallon MJ, Child R. Subchronic oral toxicity assessment of a cannabis extract. Regul Toxicol Pharmacol. 2023 Oct;144:105496. doi: 10.1016/j.yrtph.2023.105496. Epub 2023 Sep 19.

    PubMed 37734651

  • Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, Amminger GP, McGregor IS. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):525-533. doi: 10.1097/JCP.0000000000001427.

    PubMed 34121064

  • Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics. 2003 Mar-Apr;44(2):167-71. doi: 10.1176/appi.psy.44.2.167.

    PubMed 12618536

  • 11. Citalopram (Celexa ®) tablet label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf

  • 12. Morphine Sulfate tablet label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022207s010lbl.pdf

  • Iannone LF, Arena G, Battaglia D, Bisulli F, Bonanni P, Boni A, Canevini MP, Cantalupo G, Cesaroni E, Contin M, Coppola A, Cordelli DM, Cricchiuti G, De Giorgis V, De Leva MF, De Rinaldis M, d'Orsi G, Elia M, Galimberti CA, Morano A, Granata T, Guerrini R, Lodi MAM, La Neve A, Marchese F, Masnada S, Michelucci R, Nosadini M, Pilolli N, Pruna D, Ragona F, Rosati A, Santucci M, Spalice A, Pietrafusa N, Striano P, Tartara E, Tassi L, Papa A, Zucca C, Russo E, Mecarelli O; CBD LICE Italy Study Group. Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Front Neurol. 2021 May 20;12:673135. doi: 10.3389/fneur.2021.673135. eCollection 2021.

    PubMed 34093420

  • 14. Sharbaf Shoar N, Fariba KA, Padhy RK. Citalopram. StatPearls https://www.ncbi.nlm.nih.gov/books/NBK482222/

  • Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58. Epub 2011 May 4.

    PubMed 21544079

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Cannabidiol, Citalopram and Morphine in people with Cannabidiol and Drug Induced Liver Injury, run by Food and Drug Administration (FDA) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN). (time frame: Days 1 through 35). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06192589, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in